Vancomycin Flushing Syndrome Due to Oral Vancomycin in Chronic Kidney Disease Patients: A Case Report

por Yadav, Swarada, Hashmi, Muhammad Usman, Shah, Sundeep, Sarwar, Abeer, Ibrahim, Ramy
Publicado 2022

Correction: Vancomycin Flushing Syndrome Due to Oral Vancomycin in Chronic Kidney Disease Patients: A Case Report

por Yadav, Swarada, Hashmi, Muhammad Usman, Shah, Sundeep, Sarwar, Abeer, Ibrahim, Ramy
Publicado 2022

Superior Vena Cava Syndrome Due to Right Anterior Mediastinal Hematoma: A Case Report

por Ibrahim, Ramy, Yadav, Swarada, Waqar, Sumaita, Hermann, Jose Ruben, Sarwar, Abeer, Shah, Sundeep
Publicado 2022

Paget-Schroetter syndrome in the absence of common predisposing factors: a case report

por Ibrahim, Ramy, Dashkova, Irina, Williams, Myia, Kozikowski, Andrzej, Abrol, Neeraj, Gandhi, Anjula, Pekmezaris, Renee
Publicado 2017

Idiopathic Thrombocytopenia with Iron Deficiency Anemia

por Ibrahim, Ramy, Alhilli, Jaffar Ahmad, Cooper, Tyler T, Dashkova, Irina, Guy, Judah, Gandhi, Anjula, Zaman, Mohammad
Publicado 2013

A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation

por Maio, Michele, Lahn, Michael, Di Giacomo, Anna Maria, Covre, Alessia, Calabrò, Luana, Ibrahim, Ramy, Fox, Bernard
Publicado 2021

Triad of Iron Deficiency Anemia, Severe Thrombocytopenia and Menorrhagia—A Case Report and Literature Review

por Ibrahim, Ramy, Khan, Areej, Raza, Shahzad, Kafeel, Muhammad, Dabas, Ridhima, Haynes, Elizabeth, Gandhi, Anjula, Majumder, Omran L., Zaman, Mohammad
Publicado 2012

A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma

por Krug, Lee, di Pietro, Alessandra, Narwal, Rajesh, Robbins, Paul, Fu, Dongyue, Shalabi, Aiman, Ibrahim, Ramy, Calabro, Luana, Kindler, Hedy
Publicado 2013

Improved Endpoints for Cancer Immunotherapy Trials

por Hoos, Axel, Eggermont, Alexander M. M., Janetzki, Sylvia, Hodi, F. Stephen, Ibrahim, Ramy, Anderson, Aparna, Humphrey, Rachel, Blumenstein, Brent, Old, Lloyd, Wolchok, Jedd
Publicado 2010

A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma

por Rahma, Osama E, Ashtar, Ed, Ibrahim, Ramy, Toubaji, Antoun, Gause, Barry, Herrin, Vincent E, Linehan, W Marston, Steinberg, Seth M, Grollman, Frank, Grimes, George, Bernstein, Sarah A, Berzofsky, Jay A, Khleif, Samir N
Publicado 2010

Safety and disease response to MEDI-551, an anti-CD19 antibody, in chronic lymphocytic leukemia patients previously treated with rituximab

por Forero, Andres, Hamadani, Mehdi, Kipps, Thomas, Fanale, Michelle, Cuneo, Antonio, Perez de Oteyza, Jaime, Gladstone, Douglas, Andre, Marc, Bellam, Naresh, Goswami, Trishna, Ibrahim, Ramy, Schneider, Amy, Liang, Meina, Eck, Steven, Elgeioushi, Nairouz, Herbst, Ronald, Cheson, Bruce D
Publicado 2013

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker...

por Friedman, Claire F, Spencer, Christine, Cabanski, Christopher R, Panageas, Katherine S, Wells, Daniel K, Ribas, Antoni, Tawbi, Hussein, Tsai, Katy, Postow, Michael, Shoushtari, Alexander, Chapman, Paul, Karakunnel, Joyson, Bucktrout, Samantha, Gherardini, Pier, Hollmann, Travis J, Chen, Richard O, Callahan, Margaret, LaVallee, Theresa, Ibrahim, Ramy, Wolchok, Jedd
Publicado 2022

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31(st)Annual Meeting of the Society for Immunotherapy of Cancer, 2016

por Adusumilli, Prasad S., Cha, Edward, Cornfeld, Mark, Davis, Thomas, Diab, Adi, Dubensky, Thomas W., Evans, Elizabeth, Grogan, Jane L., Irving, Bryan A., Leidner, Rom S., Olwill, Shane A., Soon-Shiong, Patrick, Triebel, Frederic, Tuck, David, Bot, Adrian, Dansey, Roger D., Drake, Charles G., Freeman, Gordon J., Ibrahim, Ramy, Patel, Salil, Chen, Daniel S.
Publicado 2017

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

por Padrón, Lacey J., Maurer, Deena M., O’Hara, Mark H., O’Reilly, Eileen M., Wolff, Robert A., Wainberg, Zev A., Ko, Andrew H., Fisher, George, Rahma, Osama, Lyman, Jaclyn P., Cabanski, Christopher R., Yu, Jia Xin, Pfeiffer, Shannon M., Spasic, Marko, Xu, Jingying, Gherardini, Pier Federico, Karakunnel, Joyson, Mick, Rosemarie, Alanio, Cécile, Byrne, Katelyn T., Hollmann, Travis J., Moore, Jonni S., Jones, Derek D., Tognetti, Marco, Chen, Richard O., Yang, Xiaodong, Salvador, Lisa, Wherry, E. John, Dugan, Ute, O’Donnell-Tormey, Jill, Butterfield, Lisa H., Hubbard-Lucey, Vanessa M., Ibrahim, Ramy, Fairchild, Justin, Bucktrout, Samantha, LaVallee, Theresa M., Vonderheide, Robert H.
Publicado 2022